MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/21645515.2023.2245721

Медицинская библиотека · Human vaccines & immunotherapeutics · 2023

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.

Chen Jianmin, Jiang Feng, Zhao Chenyan, Chai Jing, Li Lanshu, Guan Qinghu, Li Xiaoyu, Wang Feiyu, Li Ansheng, Gao Hongxia, Wang Minghui, Fu Liandi, Nie Fei, Ling Weijun, Deng Haobin, Zhou Lei

Рандомизированное исследованиеКлиническое исследование III фазыСтатьяПоддержка исследования: вне правительства СШАEquivalence TrialПеревод в очереди

Аннотация

This study aimed to evaluate the immunogenicity non-inferiority and safety of the quadrivalent inactivated split-virion influenza vaccine in participants ≥ 3 years old. A total of 3,328 participants were enrolled. Participants 3-8 years old were administered one or two doses of the investigational vaccine or one dose of the control vaccine, whereas the other participants were administered only one dose of the investigational or control vaccine. The immunogenicity and occurrence of adverse events (AEs) after 30 days of full-course vaccination and serious adverse events (SAEs) within 6 months after full-course vaccination were assessed. The sero-conversion rates (SCRs) of anti-H1N1, H3N2, B(Y), and B(V) antibodies in the test group were 74.64%, 87.40%, 82.66%, and 78.89%, respectively, and their geometric mean titers were 1:250.13, 1:394.54, 1:200.84, and 1:94.91, respectively, which were non-inferior to those in the control group. The SCRs and sero-protection rates in the two-dose group of participants 3-8 years old were greater than those in the one-dose group. The incidences of total AEs and adverse reactions in the test group were 31.6% and 21.7%, respectively, which were close to those in the control group. In the two-dose group, the incidence of adverse reactions was considerably lower in the second dose (5.5%) than in the first dose (14.7%). Most AEs were grade 1 in severity, and no SAEs were recorded. The investigational vaccine had immunogenicity non-inferior to the control vaccine, and two doses were more effective than one dose in participants 3-8 years old, with a good overall safety.Trial registration: CTR20200715.

Для цитирования: Chen Jianmin, Jiang Feng, Zhao Chenyan, Chai Jing, Li Lanshu, Guan Qinghu, Li Xiaoyu, Wang Feiyu, Li Ansheng, Gao Hongxia, Wang Minghui, Fu Liandi, Nie Fei, Ling Weijun, Deng Haobin, Zhou Lei. Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.. Human vaccines & immunotherapeutics. 2023. DOI: 10.1080/21645515.2023.2245721.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.